Steven W. Paugh

Steven W. Paugh

Auto-generated profile, based on publicly available information

Steven W. Paugh

Hematological Malignancies Program, and

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2012 in Nature
Verified
Journal Article
Open access
PDF file
GRGiles Robinson
Giles Robinson
MPMatthew Parker
Matthew Parker
TKTanya A. Kranenburg
Tanya A. Kranenburg
CLCharles Lu
Charles Lu
XCXiang Chen
Xiang Chen
RGRichard J. Gilbertson
Richard J. Gilbertson
Medulloblastoma is a malignant childhood brain tumour comprising four discrete subgroups. Here, to identify mutations that drive medulloblastoma, we sequenced the entire genomes of 37 tumours and matched normal blood. One-hundred and thirty-six genes harbouring somatic mutations in this discovery set were sequenced in an additional 56 medulloblastomas. Recurrent mutations were detected in 41 genes not yet implicated in medulloblastoma; several target distinct components of the epigenetic machinery in different disease subgroups, such as regulators of H3K27 and H3K4 trimethylation in subgroups 3 and 4 (for example, KDM6A and ZMYM3), and CTNNB1-associated chromatin re-modellers in WNT-subgroup tumours (for example, SMARCA4 and CREBBP). Modelling of mutations in mouse lower rhombic lip progenitors that generate WNT-subgroup tumours identified genes that maintain this cell lineage (DDX3X), as well as mutated genes that initiate (CDH1) or cooperate (PIK3CA) in tumorigenesis. These data provide important new insights into the pathogenesis of medulloblastoma subgroups and highlight targets for therapeutic development.

1 June 2008 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
Kazuaki TakabeKazuaki Takabe
Kazuaki Takabe
SPSteven W. Paugh
Steven W. Paugh
SMSheldon Milstien
Sheldon Milstien
SSSarah Spiegel
Sarah Spiegel
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid metabolite involved in many critical cellular processes including proliferation, survival, and migration, as well as angiogenesis and allergic responses. S1P levels inside cells are tightly regulated by the balance between its synthesis by sphingosine kinases and degradation. S1P is interconvertible with ceramide, which is a critical mediator of apoptosis. It has been postulated that the ratio between S1P and ceramide determines cell fate. Activation of sphingosine kinase by a variety of agonists increases intracellular S1P, which in turn can function intracellularly as a second messenger or be secreted out of the cell and act extracellularly by binding to and signaling through S1P receptors in autocrine and/or paracrine manners. Recent studies suggest that this “inside-out” signaling by S1P may play a role in many human diseases, including cancer, atherosclerosis, inflammation, and autoimmune disorders such as multiple sclerosis. In this review we summarize metabolism of S1P, mechanisms of sphingosine kinase activation, and S1P receptors and their downstream signaling pathways and examine relationships to multiple disease processes. In particular, we describe recent preclinical and clinical trials of therapies targeting S1P signaling, including 2-amino-2-propane-1,3-diol hydrochloride (FTY720, fingolimod), S1P receptor agonists, sphingosine kinase inhibitors, and anti-S1P monoclonal antibody.

1 August 2012 in Cancer Cell
Verified
Journal Article
Closed access
KRKathryn G. Roberts
Kathryn G. Roberts
RMRyan D. Morin
Ryan D. Morin
JZJinghui Zhang
Jinghui Zhang
MHMartin Hirst
Martin Hirst
YZYongjun Zhao
Yongjun Zhao
CMCharles G Mullighan
Charles G Mullighan

1 December 2006 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
NHNitai C. Hait
Nitai C. Hait
COCarole A. Oskeritzian
Carole A. Oskeritzian
SPSteven W. Paugh
Steven W. Paugh
SMSheldon Milstien
Sheldon Milstien
SSSarah Spiegel
Sarah Spiegel

17 October 2003 in FEBS Letters
Verified
Journal Article
Closed access
SPSteven W. Paugh
Steven W. Paugh
SPShawn G. Payne
Shawn G. Payne
SBSuzanne E. Barbour
Suzanne E. Barbour
SMSheldon Milstien
Sheldon Milstien
SSSarah Spiegel
Sarah Spiegel

15 August 2008 in Blood
Verified
Journal Article
Open access
PDF file
SPSteven W. Paugh
Steven W. Paugh
BPBarbara S. Paugh
Barbara S. Paugh
MRMohamed Rahmani
Mohamed Rahmani
DKDmitri Kapitonov
Dmitri Kapitonov
JAJorge A. Almenara
Jorge A. Almenara
SSSarah Spiegel
Sarah Spiegel
The potent bioactive sphingolipid mediator, sphingosine-1-phosphate (S1P), is produced by 2 sphingosine kinase isoenzymes, SphK1 and SphK2. Expression of SphK1 is up-regulated in cancers, including leukemia, and associated with cancer progression. A screen of sphingosine analogs identified (2R,3S,4E)-N-methyl-5-(4′-pentylphenyl)-2-aminopent-4-ene-1,3-diol, designated SK1-I (BML-258), as a potent, water-soluble, isoenzyme-specific inhibitor of SphK1. In contrast to pan-SphK inhibitors, SK1-I did not inhibit SphK2, PKC, or numerous other protein kinases. SK1-I decreased growth and survival of human leukemia U937 and Jurkat cells, and enhanced apoptosis and cleavage of Bcl-2. Lethality of SK1-I was reversed by caspase inhibitors and by expression of Bcl-2. SK1-I not only decreased S1P levels but concomitantly increased levels of its proapoptotic precursor ceramide. Conversely, S1P protected against SK1-I–induced apoptosis. SK1-I also induced multiple perturbations in activation of signaling and survival-related proteins, including diminished phosphorylation of ERK1/2 and Akt. Expression of constitutively active Akt protected against SK1-I–induced apoptosis. Notably, SK1-I potently induced apoptosis in leukemic blasts isolated from patients with acute myelogenous leukemia but was relatively sparing of normal peripheral blood mononuclear leukocytes. Moreover, SK1-I markedly reduced growth of AML xenograft tumors. Our results suggest that specific inhibitors of SphK1 warrant attention as potential additions to the therapeutic armamentarium in leukemia.